Planet of the AAVs: The Spinal Cord Injury Episode.
Katerina StepankovaDaniel HorákLucia Machová UrdzíkováPublished in: Biomedicines (2021)
The spinal cord injury (SCI) is a medical and life-disrupting condition with devastating consequences for the physical, social, and professional welfare of patients, and there is no adequate treatment for it. At the same time, gene therapy has been studied as a promising approach for the treatment of neurological and neurodegenerative disorders by delivering remedial genes to the central nervous system (CNS), of which the spinal cord is a part. For gene therapy, multiple vectors have been introduced, including integrating lentiviral vectors and non-integrating adeno-associated virus (AAV) vectors. AAV vectors are a promising system for transgene delivery into the CNS due to their safety profile as well as long-term gene expression. Gene therapy mediated by AAV vectors shows potential for treating SCI by delivering certain genetic information to specific cell types. This review has focused on a potential treatment of SCI by gene therapy using AAV vectors.
Keyphrases
- gene therapy
- spinal cord injury
- spinal cord
- gene expression
- neuropathic pain
- healthcare
- end stage renal disease
- chronic kidney disease
- mental health
- genome wide
- stem cells
- ejection fraction
- blood brain barrier
- transcription factor
- risk assessment
- peritoneal dialysis
- patient reported outcomes
- social media
- health information